All In Biotech

Drug Trial Radar · NCT06258213

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers

A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Aug 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

90

Actual

Start

Jan 23, 2024

Primary completion

Jul 29, 2024

Study completion Jul 29, 2024

Sponsor

Lead sponsor
Atom Therapeutics Co., LtdIndustry
Sponsor type
Industry
First posted
Feb 14, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A randomized, double-blind, placebo-controlled, dose-escalation study will be conducted in healthy volunteers. This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ABP-745 following single (Part 1) and multiple (Part 2) oral doses.

Conditions

  • Gout
  • Acute Gout Flare
  • Gout Flares

Interventions

  • ABP-745Drug

    0.5, 5 or 25 mg tablet

  • PlaceboDrug

    Placebo tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (Safety and Tolerability)Time frame: Up to Day 14

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Worldwide Clinical Trials

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.